Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis.
Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, Lindman BR, Babaliaros V, Fearon WF, Daniels DV, Chhatriwalla AK, Kavinsky C, Gada H, Shah P, Szerlip M, Dahle T, Goel K, O'Neill W, Sheth T, Davidson CJ, Makkar RR, Prince H, Zhao Y, Hahn RT, Leipsic J, Redfors B, Pocock SJ, Mack M, Leon MB; EARLY TAVR Trial Investigators.
Généreux P, et al. Among authors: cohen dj.
N Engl J Med. 2025 Jan 16;392(3):217-227. doi: 10.1056/NEJMoa2405880. Epub 2024 Oct 28.
N Engl J Med. 2025.
PMID: 39466903
Clinical Trial.
The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes. Superiority testing was performed in the intention-to-treat population. ...CONCLUSIONS: Among patients with asymptomatic severe aortic stenosis, a strategy of ea …
The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes. Superiority testing w …